Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

A decade of incurred sample reanalysis: failures, investigations and impact.

Lee LB, Wickremsinhe ER.

Bioanalysis. 2018 Nov 1;10(21):1767-1772. doi: 10.4155/bio-2018-0214. Epub 2018 Oct 10.

PMID:
30301360
2.

Incorporating dried blood spot LC-MS/MS analysis for clinical development of a novel oncolytic agent.

Wickremsinhe ER, Callies S, Schmalz CA, Lee LB, LaBell ES, Satonin DK.

Bioanalysis. 2018 Mar 1;10(5):341-356. doi: 10.4155/bio-2017-0231. Epub 2018 Feb 16.

PMID:
29451018
4.

Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.

Salphati L, Alicke B, Heffron TP, Shahidi-Latham S, Nishimura M, Cao T, Carano RA, Cheong J, Greve J, Koeppen H, Lau S, Lee LB, Nannini-Pepe M, Pang J, Plise EG, Quiason C, Rangell L, Zhang X, Gould SE, Phillips HS, Olivero AG.

Drug Metab Dispos. 2016 Dec;44(12):1881-1889. Epub 2016 Sep 16.

PMID:
27638506
5.

Two decades of nation-wide community-based stroke support - The Singapore National Stroke Association.

Venketasubramanian N, Yin A, Lee LB, De Silva DA.

Int J Stroke. 2017 Apr;12(3):297-301. doi: 10.1177/1747493016676620. Epub 2016 Oct 24.

PMID:
27777378
6.

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.

Heffron TP, Ndubaku CO, Salphati L, Alicke B, Cheong J, Drobnick J, Edgar K, Gould SE, Lee LB, Lesnick JD, Lewis C, Nonomiya J, Pang J, Plise EG, Sideris S, Wallin J, Wang L, Zhang X, Olivero AG.

ACS Med Chem Lett. 2016 Feb 16;7(4):351-6. doi: 10.1021/acsmedchemlett.6b00005. eCollection 2016 Apr 14.

7.

The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).

Heffron TP, Heald RA, Ndubaku C, Wei B, Augistin M, Do S, Edgar K, Eigenbrot C, Friedman L, Gancia E, Jackson PS, Jones G, Kolesnikov A, Lee LB, Lesnick JD, Lewis C, McLean N, Mörtl M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Staben ST, Steinbacher S, Tsui V, Wallin J, Sampath D, Olivero AG.

J Med Chem. 2016 Feb 11;59(3):985-1002. doi: 10.1021/acs.jmedchem.5b01483. Epub 2016 Jan 20.

PMID:
26741947
8.

Reply: To PMID 24531022.

Olsen TW, Palejwala NV, Lee LB, Bergstrom CS, Yeh S.

Am J Ophthalmol. 2014 Aug;158(2):409-10. doi: 10.1016/j.ajo.2014.05.010. No abstract available.

PMID:
25085106
9.

Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.

Dail M, Wong J, Lawrence J, O'Connor D, Nakitandwe J, Chen SC, Xu J, Lee LB, Akagi K, Li Q, Aster JC, Pear WS, Downing JR, Sampath D, Shannon K.

Nature. 2014 Sep 25;513(7519):512-6. doi: 10.1038/nature13495. Epub 2014 Jul 20.

10.

Subcutaneous and periorbital emphysema following dental procedure.

Fleischman D, Davis RM, Lee LB.

Ophthalmic Plast Reconstr Surg. 2014 Mar-Apr;30(2):e43-5. doi: 10.1097/IOP.0b013e318295f982.

PMID:
24614564
11.

StomaphyX vs a sham procedure for revisional surgery to reduce regained weight in Roux-en-Y gastric bypass patients : a randomized clinical trial.

Eid GM, McCloskey CA, Eagleton JK, Lee LB, Courcoulas AP.

JAMA Surg. 2014 Apr;149(4):372-9. doi: 10.1001/jamasurg.2013.4051.

PMID:
24554030
12.

Chorioretinal folds: associated disorders and a related maculopathy.

Olsen TW, Palejwala NV, Lee LB, Bergstrom CS, Yeh S.

Am J Ophthalmol. 2014 May;157(5):1038-47. doi: 10.1016/j.ajo.2014.02.021. Epub 2014 Feb 14.

PMID:
24531022
13.

Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

O'Brien T, Oeh J, Xiao Y, Liang X, Vanderbilt A, Qin A, Yang L, Lee LB, Ly J, Cosino E, LaCap JA, Ogasawara A, Williams S, Nannini M, Liederer BM, Jackson P, Dragovich PS, Sampath D.

Neoplasia. 2013 Dec;15(12):1314-29.

14.

High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS.

Wickremsinhe ER, Lee LB, Schmalz CA, Torchia J, Ruterbories KJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Aug 1;932:117-22. doi: 10.1016/j.jchromb.2013.06.008. Epub 2013 Jun 13.

PMID:
23831704
15.

Chronic, recurrent dacryocystitis from a BB in the lacrimal sac.

Lee LB, Dutton JJ.

Ophthalmic Plast Reconstr Surg. 2014 Mar-Apr;30(2):e40-1. doi: 10.1097/IOP.0b013e3182937632.

PMID:
23719199
16.

Candida species lens abscesses in infants with a history of neonatal Candida sepsis.

Couser NL, Hubbard GB, Lee LB, Hutchinson AK, Lambert SR.

J AAPOS. 2013 Apr;17(2):208-10. doi: 10.1016/j.jaapos.2012.11.006.

17.

Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.

Tan N, Wong M, Nannini MA, Hong R, Lee LB, Price S, Williams K, Savy PP, Yue P, Sampath D, Settleman J, Fairbrother WJ, Belmont LD.

Mol Cancer Ther. 2013 Jun;12(6):853-64. doi: 10.1158/1535-7163.MCT-12-0949. Epub 2013 Mar 8.

18.

Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.

Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, Savage H, Guan Z, Hong R, Kassees R, Lee LB, Risom T, Gross S, Liederer BM, Koeppen H, Skelton NJ, Wallin JJ, Belvin M, Punnoose E, Friedman LS, Lin K.

Clin Cancer Res. 2013 Apr 1;19(7):1760-72. doi: 10.1158/1078-0432.CCR-12-3072. Epub 2013 Jan 3.

19.

Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.

Salphati L, Heffron TP, Alicke B, Nishimura M, Barck K, Carano RA, Cheong J, Edgar KA, Greve J, Kharbanda S, Koeppen H, Lau S, Lee LB, Pang J, Plise EG, Pokorny JL, Reslan HB, Sarkaria JN, Wallin JJ, Zhang X, Gould SE, Olivero AG, Phillips HS.

Clin Cancer Res. 2012 Nov 15;18(22):6239-48. doi: 10.1158/1078-0432.CCR-12-0720. Epub 2012 Sep 19.

20.

The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α.

Heffron TP, Salphati L, Alicke B, Cheong J, Dotson J, Edgar K, Goldsmith R, Gould SE, Lee LB, Lesnick JD, Lewis C, Ndubaku C, Nonomiya J, Olivero AG, Pang J, Plise EG, Sideris S, Trapp S, Wallin J, Wang L, Zhang X.

J Med Chem. 2012 Sep 27;55(18):8007-20. Epub 2012 Sep 11.

PMID:
22946614
21.

Beyond amyloid: the future of therapeutics for Alzheimer's disease.

Lane RF, Shineman DW, Steele JW, Lee LB, Fillit HM.

Adv Pharmacol. 2012;64:213-71. doi: 10.1016/B978-0-12-394816-8.00007-6. Review.

PMID:
22840749
22.

Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.

Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X.

Drug Metab Dispos. 2012 Sep;40(9):1785-96. doi: 10.1124/dmd.112.046052. Epub 2012 Jun 13.

PMID:
22696419
23.

GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.

Wallin JJ, Guan J, Prior WW, Lee LB, Berry L, Belmont LD, Koeppen H, Belvin M, Friedman LS, Sampath D.

Clin Cancer Res. 2012 Jul 15;18(14):3901-11. doi: 10.1158/1078-0432.CCR-11-2088. Epub 2012 May 14.

24.

Logarithmic transformation of spectral-domain optical coherence tomography data in uveitis-associated macular edema.

Payne JF, Bruce BB, Lee LB, Yeh S.

Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):8939-43. doi: 10.1167/iovs.11-8193.

PMID:
21948555
25.

Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies.

Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjänheikki J, Fillit HM.

Alzheimers Res Ther. 2011 Sep 28;3(5):28. doi: 10.1186/alzrt90.

26.

Intraoperative spectral-domain optical coherence tomography during complex retinal detachment repair.

Lee LB, Srivastava SK.

Ophthalmic Surg Lasers Imaging. 2011 Aug 11;42 Online:e71-4. doi: 10.3928/15428877-20110804-05.

PMID:
21830748
27.

Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.

Salphati L, Lee LB, Pang J, Plise EG, Zhang X.

Drug Metab Dispos. 2010 Sep;38(9):1422-6. doi: 10.1124/dmd.110.034256. Epub 2010 Jun 3.

PMID:
20522663
28.

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.

Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, Sampath D, Friedman LS, Belvin M.

Cancer Res. 2010 Feb 1;70(3):1164-72. doi: 10.1158/0008-5472.CAN-09-2525. Epub 2010 Jan 26.

29.

Expanding ICU facilities in an epidemic: recommendations based on experience from the SARS epidemic in Hong Kong and Singapore.

Gomersall CD, Tai DY, Loo S, Derrick JL, Goh MS, Buckley TA, Chua C, Ho KM, Raghavan GP, Ho OM, Lee LB, Joynt GM.

Intensive Care Med. 2006 Jul;32(7):1004-13. Epub 2006 Mar 29.

PMID:
16570146
30.

Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis.

Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Gröne HJ, Lipson KE, Huber PE.

J Exp Med. 2005 Mar 21;201(6):925-35.

31.

The challenge of providing holistic care in a viral epidemic: opportunities for palliative care.

Leong IY, Lee AO, Ng TW, Lee LB, Koh NY, Yap E, Guay S, Ng LM.

Palliat Med. 2004 Jan;18(1):12-8.

PMID:
14982202
32.

Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.

Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA.

Clin Cancer Res. 2003 Nov 15;9(15):5729-34.

33.

The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents.

Haas JS, Lee LB, Kaplan CP, Sonneborn D, Phillips KA, Liang SY.

Am J Public Health. 2003 Dec;93(12):2105-10.

34.

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.

Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK.

Mol Cancer Ther. 2003 Oct;2(10):1011-21.

35.

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.

Mol Cancer Ther. 2003 May;2(5):471-8.

36.

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM.

Clin Cancer Res. 2003 Jan;9(1):327-37.

37.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.

Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16.

38.

The malpractice triangle.

Lee LB.

Dent Econ. 1976 Jun;66(6):47-53. No abstract available.

PMID:
1074441
39.

Nutrition in periodontal disease.

Lee LB, van der Werf K.

N M Dent J. 1974 Feb;24(4):14-5. No abstract available.

PMID:
4524134
40.

Nutrition and preventive dentistry.

Lee LB, Van der Werf K.

N M Dent J. 1973 Aug;24(2):10-1. No abstract available.

PMID:
4521984
41.

Letters to the editor. "Why foreign dentists must pass an exam".

Lee LB.

Dent Surv. 1970 Dec;46(12):47. No abstract available.

PMID:
5278436

Supplemental Content

Support Center